Maxim Group analyst Jason McCarthy maintained a Buy rating on SELLAS Life Sciences Group (SLS – Research Report) yesterday and set a price target of $12.00. The company’s shares opened today at $3.26.
McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Oncolytics Biotech, and NLS Pharmaceutics. According to TipRanks, McCarthy has an average return of -33.1% and a 19.92% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for SELLAS Life Sciences Group with a $10.00 average price target.
See today’s best-performing stocks on TipRanks >>
SLS market cap is currently $68.35M and has a P/E ratio of -1.49.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutics for cancer indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. Its products include galinpepimut-S and nelipepimut-S. The company was founded on April 3, 2006 and is headquartered in New York, NY.
Read More on SLS:
- Sellas Life Sciences to hold a conference call
- Sellas Life Sciences to host KOL webinar on GPS AML program
- SELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program
- Sellas Life Sciences appoints Elnatan as VP, Head of Regulatory Affairs, CMC
- SELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairs
